Would you like to receive important updates about Incyte Corp like earnings dates and more?
The Year To Date (YTD) return is -14.73%.
The 52 Week Low stock price is 80.85 set on Fri, Feb 9, 2018 which is 9 days ago.
The current price per share is 6.41% above the 52 week low.
The 52 Week High stock price is $153.15 set on Wed, Mar 15, 2017 which is 340 days ago.
The current price per share is -43.83% below the 52 week high.
The All Time High stock price is $153.15 set on Wed, Mar 15, 2017 which is 340 days ago.
The current price per share is -43.83% below the all time high.
The Incyte 5 year stock chart shows the historical prices over the previous 60 months.
The Incyte 1 year stock chart shows the historical prices over the previous 12 months.
The 50 Day Moving Average is at $129.58 which is 33.61% above the stock price of $86.03.
The 200 Day Moving Average is at 124.16 which is 30.71% above the stock price of $86.03.
Because both the 50 DMA and 200 DMA are above the current stock price, this can be considered a bearish technical indicator.
Since the stock price is very far from both moving averages, a price retracement towards the moving averages should not be unexpected.
Incyte Corp is a Health Care stock that trades on the NASDAQ and has a market capitalization of $18.16 Billion.
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.
Below are several other Biotech & Pharma stocks include AbbVie Inc (ABBV), Allergan PLC (AGN), Alexion Pharmaceuticals Inc (ALXN), Amgen Inc (AMGN), Biogen Inc (BIIB), BioMarin Pharmaceutical Inc (BMRN), Bristol-Myers Squibb Co (BMY), Celgene Corp (CELG), Endo International PLC (ENDP), Gilead Sciences Inc (GILD), .
The EPS is -$1.56 and the P/E Ratio is 0.
A negative Earnings Per Share (EPS) means that this company is losing money and not profitable at this time.
Stocks can make big percentage moves on the earnings announcement.
Companies announce earnings either before the market open or after the close.
The Earnings Release Date for Incyte Corp was Tue, Oct 31, 2017.
Since this earnings release 110 days ago, the stock price is down by -24.69%.
Many investors know the importance of a companies earnings report. Also, the market reaction to the earnings release can be even more important and can help in making a prediction of a future price forecast of the shares.
A significant post earnings announcement percentage move can continue or reverse an existing trend for several days or weeks after the earnings date.
The most recent Earnings Release Date was on Thu, Feb 15, 2018, which was 3 days ago.
Since this earnings date, the stock price is down by -2.43%.
INCY currently does not pay a dividend.
You may like this list of best dividend stocks of 2018.